Testosterone therapy in HIV wasting syndrome: Systematic review and meta-analysis

Lancet Infectious Diseases

Volumn 2, Issue 11, 2002, Pages 692-699

  Kong, Anthony ^a,c   Edmonds, Polly ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c 31 Anne Goodman House ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MEGESTROL ACETATE; OXANDROLONE; PLACEBO; RECOMBINANT GROWTH HORMONE; TESTOSTERONE; THALIDOMIDE;

ACNE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; BODY MASS; BODY WEIGHT; CACHEXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXERCISE; FATIGUE; GYNECOMASTIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MASTALGIA; META ANALYSIS; MULTICENTER STUDY; MUSCLE STRENGTH; MUSCLE WEAKNESS; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 0036839995     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(02)00441-3     Document Type: Review

References (46)

1. Strawford A, Hellerstein M. The aetiology of wasting in HIV and AIDS. Semin Oncol 1998; 25: 70-81.
2. Ott M, Lembcke B, Fischerb H, et al. Early changes of body composition in human immunodefiency virus-infected patients: Tetrapolar body impedance analysis indicates significant malnutrition. Am J Clin Nutr 1993; 57: 15-19.
3. Kofler DP, Tierney A, Pierson RN. Magnitude of body cell mass depletion and timing of death from wasting in AIDS. Am J Clin Nutr 1989; 50: 444-47.
4. Kotler DP, Wang J, Pierson RN. Body composition studies in patients with acquired immunodefiency syndrome. Am J Clin Nutr 1985; 42: 1255-65.
5. Nemechek PM, Polsky B, Gottlieb MS. Treatment guidelines for HIV-associated wasting. Mayo Clin Proc 2000; 75: 386-94.
6. Wang ZM, Pierson RN Jr, Heymsfield SB. The five-level model: A new approach to organizing body composition research. Am J Clin Nutr 1992; 56: 19-28.
7. Silva M, Skolnik PR, Gorbach SL, et al. The effect of protease inhibitos on weight and body composition in HIV-infected patients. AIDS 1998; 12: 1645-51.
8. Pernerstorfer-Schoen H, Schndler K, Parschalk B, et al. Beneficial effects ofprotease inhibitors on body composition and energy expenditure: A comparison between HIV-infected and AIDS patients. AIDS 1999; 13: 2389-96.
9. Engelson ES, Pi-Sunyer FX, Kotler DP. Effects of megestrol acetate therapy on body composition and circulating testosterone concentrations in patients with AIDS. AIDS 1995; 9: 1107-08.
10. Von Roenn JH, Murphy RL, Weber KM, Williams LM, Weitzman SA. Megestrol acetate for treatment of cachexia associated with HIV infection. Ann Intern Med 1988; 109: 840-41.
11. Von Roenn JH, Murphy RL, Wegener N. Megestrol acetate for treatment of anorexia and cachexia associated with HIV infection. Semin Oncol 1990; 17: 13-16.
12. Rebuck JA, Fish DN. Thalidomide pros and cons. Am J Nurs 1998; 98: 63.
13. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: A randomised, double-blind, placebo-controlled clinical trial. AIDS 1996; 10: 1501-07.
14. Kaplan G, Thomas S, Fierer DS, et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses 2000; 16: 1345-55.
15. Waters D, Danska J, Hardy K, Koster F, Qualls C, Nickell D. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. Ann Intern Med 1996; 125: 865-72.
16. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting. Ann Intern Med 1996; 125: 873-82.
17. Mulligan K, Tai VW, Schambelan M. Effects of chronic growth hormone treatment on energy intake and resting energy metabolism in patients with HIV-associated wasting - A clinical research centre study. J Clin Endocrin Metab 1998; 84: 1288-93.
18. Croxson TC, Chapman WE, Miller LK, Levitt CD, Semie R, Zumoff B. Changes in the hypothalamic-pituitary-gonadal axis in human immunodefiency virus-infected homosexual men. J Clin Endocrinol Metab 1989; 68: 317-21.
19. Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1998; 84: 611-16.
20. Grinspoon S, Corcoran C, Lee K, et al. Loss of lean body and muscle mass corelates with androgen levels in hypogonal men with acquired immunodefiency wyndrome and wasting. J Clin Endocrinol Metab 1996; 81: 4051-58.
21. Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonal men. J Clin Endocrinol Metab 1997; 82: 407-13.
22. Brodsky IG, Balagopal P, Sreekumaran Nair K. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men - A clinical research centre study. J Clin Endocrinol Metab 1996; 81: 3469-75.
23. Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men - A clinical research centre study. J Clin Endocrinol Metab 1996; 81: 3578-83.
24. Bhasin S, Storer TW, Berman N, et al, The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. NEJM 1996; 335: 1-7.
25. Grinspoon S, Corcoran C, Askari H, et al. Effects of androgen administration in men with the AIDS wasting syndrome. Ann Intern Med 1998; 129: 18-26.
26. Grinspoon S, Corcoran C, Parlman K, et al. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. Ann Intern Med 2000; 133: 345-55.
27. Bhasin S, Storer TW, Javanbakht M, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 2000; 283: 763-70.
28. Chlebowski RT, Grosvernor MB, Bernhard NH, Morales Ls, Bulcavage LM. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol 1989; 84: 1288-93.
29. Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R. Oxandrolone in AIDS-wasting myopathy. AIDS 1996; 10: 1657-62.
30. Miller K, Corcoran C, Armstrong C, et al. Trandermal testosterone administration in women with acquired immunodefiency syndrome wasting: A pilot study. J Clin Endocrinol Metab 1998; 83: 2717-25.
31. Bhasin S, Storer TW, Asbel-Sethi N, et al. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodefiency virus-infected men with low testosterone levels. J Clin Endocrinol Metab 1998; 83: 3155-62.
32. Coodley GO, Coodley Mk. A trial of testosterone therapy for HIV-associated weight loss. AIDS 1997; 11: 1347-52.
33. Dobs AS, Cofrancesco J, Nolten W, et al. The use of a transcrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodefiency virus infection. Am J Med 1999; 107: 126-32.
34. Gold J, High HA, Li Y, et al. Safety and efficacy of nandrolone decanoate for treatment of wasting in patiens with HIV infection. AIDS 1996; 10: 745-52.
35. Grinspoon S, Corcoran C, Anderson E, et al. Sustained anabolic effects of long-term androgen administration in men with AIDS wasting. Clin Infect Dis 1999; 28: 634-36.
36. Hengge UR, Bausmann M, Maleba R, Brockmeyer NH, Goos M. Oxymetholone promotes weight gain in patients with advanced human immunodefiency virus (HIV-1) infection. Br J Nutr 1996; 75: 129-138.
37. Rabkin J, Wagner G, Rabkin R. Testosterone therapy for human immunodefiency virus-positive men with and without hypogonadism. J Clin Psychopharmacol 1999; 19: 19-27.
38. Rabkin JG, Ferrando S, Wagner GJ, Rabkin R. DHEA treatment for HIV positive patients: Effects on mood, androgenic and anabolic parameters. Psychoneuroendocrinology 1999; 25: 53-68.
39. Rabkin JG, Wagner G, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiarty 2000; 57: 141-47.
40. Sattler FR, Jaque SV, Schroeder ET, et al. Effects of pharamacological doses of nandrolone decoate and progressive resistance training in immunodefiency patients infected with human immmunodefiency virus. J Clin Endocrinol Metab 1999; 84: 1268-76.
41. Strawford A, Barbieri T, Van Loan M, et al. Resistance exercise and supraphysiological androgen therapy in eugonadal men with HIV-related weight loss. JAMA 1999; 281: 1282-90.
42. Strawford A, Barbieri T, Neese R, et al. Effects of nandrolone decanoate in borderline hypogonadal men with HIV associated weight loss. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 137-146.
43. Van Loan, Strawford A, Jacob M, Hellerstein M. Monitoring changes in fat-free mass in HIV-positive men with hypotestosteroneaemia and AIDS wasting syndrome treated with gonadal hormone replecement therapy. AIDS 1999; 13: 241-49.
44. Wagner GJ, Rabkin JG, Rabkin R. Effects of testosterone on weight and bodt composition in men with human immunodefiency virus-related weight loss. Nutr Res 1999; 19: 227-33.
45. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisolm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999; 353: 2093-99.
46. Roubenoff R, McDermott A, Weiss L, et al. Short term progressive resistance training increases strength and lean body mass in adults infected with human immunodefiency virus. AIDS 1999; 13: 231-39.